Nine of the 54 private, clinical-stage biotechs in the Class of 2003 have reached the market with a drug. Eight acquired the assets through in-licensing or M&A; the exception was IDEA AG's Directin ketoprofen, a generic delivered using the company's Transfersome gel carrier. Overall, the group of nine has raised at least $1.8 billion since inception. $M; Source: BCIQ: BioCentury Online Intelligence

Company

Raised

Focus

Marketed drug(s) [drug origin]

Sales

Basilea Pharmaceutica AG (SIX:BSLN) [spinoff from Roche (SIX:ROG; OTCQX:RHHBY)]

$556.8

Biology: antibacterial, antifungal and dermatology discovery

Toctino alitretinoin (BAL4079) [Roche]; Zeftera/Zevtera ceftobiprole (BAL5788) [Basilea/Roche]

2009 Toctino sales: CHF17.3M($16.7M); Zeftera/ Zevtera sales: NA